Holen Sie sich die Stockscreener-App
12.43
1.64%
0.20
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
Day One Biopharmaceuticals (DAWN) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Day One Biopharmaceuticals CEO sells shares for $144,130 By Investing.com - Investing.com Nigeria
Day one biopharmaceuticals general counsel sells $55,580 in stock - Investing.com
Day One Biopharmaceuticals CEO sells shares for $144,130 - Investing.com India
Day one biopharmaceuticals' COO York sells $52,278 in stock - Investing.com
Day one biopharmaceuticals general counsel sells $55,580 in stock By Investing.com - Investing.com UK
Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Monday - MarketBeat
TimesSquare Capital Management LLC Has $21.68 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Day One Bio's Talks With FDA Help Secure Glioma Drug Approval - Clinical Leader
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect? - Yahoo Finance
New Strong Buy Stocks for February 13th - Yahoo Finance
The Goldman Sachs Group Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $43.00 - MarketBeat
Day One Biopharmaceuticals to Host Conference Call to Discuss Q4 and Full-Year 2024 Financial Results and Corporate Progress - Nasdaq
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 - GlobeNewswire
Day One (DAWN) Q4 Earnings Call: Key Strategic Updates Coming February 25 - StockTitan
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $43.00 at The Goldman Sachs Group - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Analysts - Defense World
Day One Bio Aims To Shorten the Time Gap On Cancer Treatments For Kids - Life Science Leader Magazine
Day One Biopharmaceuticals Inc (DAWN) Shares Up Despite Recent Market Volatility - The News Heater
The Top 12 Companies Hiring in Biopharma Now - BioSpace
A closer look at Day One Biopharmaceuticals Inc (DAWN)’s stock price trends - US Post News
Balance Sheet Insights: Day One Biopharmaceuticals Inc (DAWN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Financial Metrics Unveiled: Ginkgo Bioworks Holdings Inc (DNA)’s Key Ratios in the Spotlight - The Dwinnex
How To Trade (DAWN) - Stock Traders Daily
You might want to take a look at Day One Biopharmaceuticals Inc (DAWN) now - SETE News
Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer - Seeking Alpha
SG Americas Securities LLC Buys Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Pediatric Brain Tumor Foundation welcomes Day One Biopharmaceuticals’ renowned Dr. Samuel C. Blackman to its Board of Directors - Yahoo Finance
SG Americas Securities LLC Acquires Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Reviewing Day One Biopharmaceuticals (NASDAQ:DAWN) and Nature’s Sunshine Products (NASDAQ:NATR) - Defense World
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
(DAWN) Trading Report - Stock Traders Daily
Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? - Yahoo Finance
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues 8-K Filing Detailing Financial Metrics and Future Milestones - Defense World
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Analysts - Defense World
(DAWN) Technical Pivots with Risk Controls - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities - GlobeNewswire
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate - The Bakersfield Californian
Day One Biopharmaceuticals Reports Strong $57.2M Revenue for First-Year OJEMDA Sales - StockTitan
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low – What’s Next? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week LowTime to Sell? - MarketBeat
Bank of America Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00 - Defense World
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):